Hypothyroidism affects about 3.7% of the general population in the United States [1] , reaching levels of up to 8% in areas with high prevalence of iodine deficiency [2] . At first sight, treatment for hypothyroidism, regardless of its etiology, seems quite straightforward. According to current guidelines the standard of care is treatment based on hormonal replacement therapy with daily administration of levothyroxine, the pro-hormone produced exclusively by the thyroid gland [3] . The rationale is that the deiodinases, thioredoxin-fold containing selenoenzymes that metabolize thyroid hormone and are present in multiple extrathyroidal tissues, activate thyroxine (T 4 ) and produce physiological amounts of the biologically active thyroid hormone, triiodothyronine (T 3 ) [4] . The observation that circulating levels of T 3 and TSH can be normalized in levothyroxine-treated hypothyroid patients reassures physicians that euthyroidism is achieved and probably contributed for the replacement of porcine thyroid preparations by the synthetic form of levothyroxine currently used [5, 6] . In fact, monitoring serum levels of TSH (and free T 4 (FT 4 )) became an integral part of the routine to follow the therapeutic efficacy of thyroid hormone replacement. However, despite normalization of these biochemical parameters, about 15% of those treated with levothyroxine replacement therapy alone do not achieve clinical euthyroidism and experience some level of psychological impairment [7] .
T 3 enters the target cells through a few specific thyroid hormone transporters, including monocarboxylate transporter (MCT)8, MCT10, and organic anion-transporting polypeptide 1C1 (OATP) [8] . Once inside the cells, T 3 gains access to the cell nucleus where it interacts with two forms of nuclear receptors (TR ␣ and TR ␤ ); both TRs are unevenly distributed throughout the body, with virtually every cell expressing either one or both receptors. This modulates the expression of specific sets of T 3 -responsive genes, thus producing T 3 -dependent biological effects, e.g. positive cardiac chronotropism, bone resorption, acceleration of energy expenditure [9] [10] [11] ( fig. 1 ).
In healthy adult individuals, about 80-90% of the extrathyroidal T 3 is produced by deiodination of T 4 via the type I (D 1 ) and type II (D 2 ) deiodinases [12, 13] , which are widely expressed throughout extrathyroidal organs and tissues: D 1 , in liver and kidney, and D 2 , in the central nervous system, bone, skin, pituitary gland, brown adipose tissue and in minute amounts in skeletal muscle and heart [14, 15] . Thus, there are two sources of T 3 bound to tissue TR at any given time, i.e. (i) direct thyroid secretion or (ii) extrathyroidal deiodination of T 4 [14, 16] . There is also a third deiodinase, D 3 , which can inactivate both T 4 and T 3 and is expressed mostly during embryonic life [17] ; in healthy adults, D 3 expression remains only in a handful of tissues, including brain, skin, heart and pancreatic ␤ -cells [14, 18] . However, during disease processes, D 3 expression can be enhanced severalfold or ectopically activated in most tissues, including liver, skeletal muscle and heart via signals such as ischemia and/or hypoxia [19, 20] .
The First Question: Can Plasma and Tissue T 3 Concentrations Be Normalized in LevothyroxineTreated Hypothyroid Individuals? Serum T 3 concentrations are expected to be normal in levothyroxine-treated hypothyroid individuals [21] [22] [23] . This would indicate that the deiodinase pathways are sufficient to normalize T 3 levels in the plasma, provided that enough T 4 is available. However, a recent large-scale cross-sectional study involving about 3,900 euthyroid volunteers and about 1,800 athyreotic patients kept on replacement therapy with levothyroxine indicates that serum T 3 is consistently lower in the hypothyroid patients, although within the normal range [24] . Furthermore, in approximately 15% of these hypothyroid patients, serum T 3 is not normalized despite normal serum TSH [24] . In addition, it seems that further increases in the dose of levothyroxine would not result in normalization of serum T 3 without bringing serum TSH below the normal range. Of note, when all individuals are stratified as a function of their serum TSH, it is clear that for any given serum TSH, the levothyroxine-treated hypothyroid patients exhibit significantly lower serum T 3 [24] .
One additional point to keep in mind is that, as opposed to T 4 , T 3 is mostly an intracellular hormone [14, 25] . Yes, it is true that plasma and tissue T 3 are at equilibrium at all times, but the sizes of both pools are not the same [14] and both T 3 production and T 3 degradation are intracellular events [26, 27] . Deiodinase-mediated T 3 production takes place inside the T 3 -target cells and thus in any given cell there is a chance that the TR-bound T 3 was produced locally (within that very same cell) and found its way to the cell nucleus before exiting the cell or reaching the plasma ( fig. 2 ). The odds of this happening vary from tissue to tissue and depend among other things on the local activity of the deiodinases. At the same time, D 3 -mediated T 2 inactivation also takes place inside the cells and thus some of the T 3 produced intracellularly might be degraded before reaching the plasma [27] . Thus, plasma T 3 level is a poor predictor of tissue T 3 concentration because it does not account for the intracellular production/inactivation of T 3 via the deiodinase pathways. As a consequence, a normal serum T 3 does not mean that the T 3 content in all tissues is normal. In fact, a mouse with targeted inactivation of D 2 (D 2 KO) has nor-mal serum T 3 levels, but its brain has only half as much T 3 when compared to a normal mouse [28, 29] . Even the mouse with combined D 1 /D 2 inactivation exhibits normal serum T 3 , revealing a remarkable ability of the murine thyroid to upregulate T 3 secretion when extrathyroidal T 3 production is abolished [30, 31] . A similar compensatory mechanism is expected to exist in humans, even though the human thyroid contributes much less to the daily T 3 production. Thus, based on the mouse studies, it is very unlikely that patients with a 'defect' in the activating deiodinase pathway would be identified by a low serum T 3 . Remarkably, each of these animals has a normal serum T 3 concentration and an increased serum T 4 concentration. The elevations in serum T 4 concentration may result from increased thyroidal secretion and/or decreased clearance, but in either case it is fascinating that the hypothalamic-pituitary-thyroid axis could be wired such that adjustments in serum T 4 concentrations are made in order to maintain serum T 3 concentrations [32] . Thus, it is tempting to speculate that serum T 3 plays a critical role for some cells/tissues, perhaps the ones that do not exhibit significant deiodinase expression.
Only direct measurements of tissue T 3 can answer the first question. Human tissues have been processed for T 3 content largely in the context of embryonic development or non-thyroidal illnesses [33] [34] [35] , and not to address the 'first' question. Only studies in rats have addressed this point and the answer is a resonant 'no', i.e. extrathyroidal metabolism of T 4 does not normalize T 3 content in most tissues [36] . However, prudence should be exercised while extrapolating rodent data to humans given that in rats the thyroidal contribution to T 3 production is much larger than in humans, about 40% [14] . Nonetheless, when thyroidectomized rats were given a range of T 4 doses (0.2-8.0 g/100 g b.w./day), no single dose of T 4 was able to restore normal serum TSH, T 4 and T 3 , as well as T 4 and T 3 in all tissues, or at least to restore T 3 simultaneously in plasma and all tissues, except for the brain [36] . Indeed, central to our discussion is the fact that T 3 content in the cerebral cortex and cerebellum was indeed normalized over a wide range of T 4 doses, even by doses that were not sufficient to normalize serum TSH [36] ( fig. 3 ) . Thus, the normal rat brain (and probably the human brain as well) contains a highly efficient D 2 -mediated mechanism that maintains its T 3 concentration based on circulating T 4 . This agrees with the undeniable observation that about 85-90% of all patients with hypothyroidism on levothyroxine therapy alone are clinically and biochemically euthyroid, living normal healthy lives. The fascinating aspect of the thyroid hormone transport across cell membranes combined with the deiodinase-mediated control of thyroid hormone action is that thyroid hormone signaling can be customized in a celland time-specific fashion, independently of serum T 3 lev- els [8, 11, 16] . In fact, in healthy adult individuals, serum levels of T 4 and T 3 are remarkably constant throughout life [37] , unlike the T 3 tissue content that can change rapidly in response to a number of developmental, metabolic and environmental cues [38] . Thus, it is logical to suppose that those patients who still experience neurocognitive impairment despite normalization of serum TSH, T 4 and T 3 concentrations lack sufficient T 3 in discrete brain areas due to a variability/defect in D 2 and/or D 3 pathways or thyroid hormone transport in the brain.
Deiodinase Pathways
Loss-of-function mutations have not been reported in any of the deiodinase genes. However, there is a report of two families in which 3 affected individuals exhibited transient growth retardation as a result of defective deiodinase expression due to a broad deficiency in selenoprotein synthesis [39] . This is an extremely rare syndrome that affects the synthesis of the three deiodinases. No data are available on whether such individuals exhibit alterations in tissue T 3 content. However, because it is so rare, it is unlikely to impact significantly the present discussion.
A D 1 -deficient mouse (D 1 KO) exhibits elevated serum levels of T 4 and rT 3 , whereas serum TSH and T 3 as well as several indices of peripheral thyroid status are unaffected [40, 41] . However, D 1 deficiency results in increased fecal excretion of endogenous iodothyronines suggesting that D 1 may play a major role in limiting the impact of iodine deficiency [41] . At the same time, in humans a single nucleotide polymorphism rs2235544 of DIO1 gene has been identified [42] in association with an increase in free T 3 and a decrease in FT 4 and rT 3 with no effect on serum TSH levels. Similarly, carriers of the D 1b -G/T (rs12095080) allele in elderly individuals had higher serum T 3 and T 3 / rT 3 [43] . On the other hand, D 1a -C/T (rs11206244) carriers had higher serum FT 4 and rT 3 , lower T 3 , and lower T 3 / rT 3 [43] . Despite biochemical differences in thyroid hormone serum levels, no data are available regarding tissue T 3 levels and, more importantly, no clinical syndrome has been identified in carriers of these polymorphisms.
The D 2 KO mouse exhibits a rich phenotype based on alterations of tissue T 3 . The BAT [44] [45] [46] , brain and pituitary gland [31, 47] , skeleton [48] , skeletal muscle [49, 50] and lungs [51] have all been extensively studied with major phenotypes attributed to deficient local generation of T 3 via the D 2 pathway. This of course opens the door for the existence of individuals with clinical syndromes caused by potential variability/defects in the D 2 pathway. This is particularly true for the brain, where T 3 content is dramatically affected by the D 2 pathway [31, 52] . D 2 is responsible for more than half of the T 3 present in the murine brain [52] . Accordingly, D 2 KO animals have half as much brain T 3 content as their wild-type siblings [31] , greatly supporting the idea that any interference in the D 2 pathway could affect brain function and/or result in intellectual or cognitive symptoms.
A potentially relevant polymorphism in the DIO2 gene (Thr92AlaD 2 ) has been described in about 15% of normal individuals [53] ( fig. 4 a, b) . This was originally associated with insulin resistance and increased BMI [53] , and subsequently with type 2 diabetes mellitus [54] . A recent case-control study with 1,057 type 2 diabetes patients and 516 non-diabetic subjects indicated that the frequencies of D 2 Ala92Ala homozygosity were 16.4% (n = 173) versus 12.0% (n = 62) in diabetic versus controls, respectively, resulting in an adjusted odds ratio of 1.41 (CI 95% 1.03-1.94, p = 0.03) [55] . These data indicate that the homozygosity for D 2 Thr92Ala polymorphism is associated with increased risk for type 2 diabetes, a conclusion that was supported by a meta-analysis including 11,033 individuals [55] . Today there is a much broader spectrum of diseases and conditions that have been associated with the Thr92AlaD 2 polymorphism, including mental retardation [56] , hypertension [57] , osteoarthritis [58] , bipolar disorder [59] , clinical course and myocardial remodeling [60] , accelerated bone turnover [61] , response to lung injury [51, 62] , indicating that indeed this locus (and the Thr92AlaD 2 polymorphism) is clinically relevant ( table 1 ). Within the context of this discussion, the logical assumption is that the Thr92AlaD 2 polymorphism results in decreased D 2 activity and thus localized tissue T 3 deficiency and hypothyroidism. However, different groups have failed to detect differences in enzyme kinetics (K m (T 4 ) and V max ) of the Thr92AlaD 2 protein when transiently expressed in cultured cells [54, 63] . A single study in tissue samples of individuals with the Thr92AlaD 2 polymorphism revealed decreased V max in biopsies of skeletal muscle and thyroid gland [54] . However, the data in skeletal muscle have since lost relevance given the subsequent discovery that special technical considerations are needed to correctly assay skeletal muscle D 2 activity [15, 64] , which were not considered in the said study [54] . Nevertheless, the reported decrease in thyroidal Thr92AlaD 2 V max remains unchallenged, albeit not yet reproduced by other groups. Two studies in patients indirectly support the view that Thr92AlaD 2 is a catalytically less active enzyme: (i) higher doses of levothyroxine were needed to achieve target TSH levels in 191 thyroid- ectomized individuals carrying Thr92AlaD 2 polymorphism [65] and (ii) the finding that the Thr92AlaD 2 polymorphism is associated with a delayed T 3 secretion in response to TRH stimulation [66] . Furthermore, all studies agree that patients with the Thr92AlaD 2 polymorphism have no alterations in all other thyroid function tests [63] . At the same time, it is important to highlight that the literature about the Thr92AlaD 2 polymorphism is controversial, with poor reproducibility amongst different studies [67] [68] [69] [70] [71] [72] . This suggests that additional unidentified linkage factors such as ethnic background could play a significant role in the physiological and clinical relevance of the Thr92AlaD 2 polymorphism [71, 73] . If future studies by other groups identify and isolate such factors and confirm the observation that Thr92AlaD 2 polymorphism limits D 2 's ability to produce T 3 , then 'yes' a variability/defect in the deiodination pathway that controls tissue T 3 could be clinically relevant based on the multiple phenotypes associated with said polymorphism. At the time of this writing, other DIO2 polymorphisms have been reported, but their clinical relevance is even less well established [74] .
The D 3 KO mouse exhibits the richest phenotype of all deiodinase KO animals, which stems from elevated tissue T 3 during developmental and post-natal life [18, [75] [76] [77] . The D 3 KO mouse has central hypothyroidism (as a result of enhanced T 3 signaling in the hypothalamus), growth delay and a major central nervous system phenotype including problems with survival and maturation of cone photoreceptors [77] and in cochlear development and auditory function [78] , as well as aggressiveness and infertility [75, 76, 79] . However, despite the potential for multiple clinical symptoms in humans, no relevant DIO3 mutations or polymorphisms or mutations have been described in humans that are relevant for the 'second' question.
Thyroid Hormone Transport Pathways
It is clear that localized thyroid hormone deficiency in the brain could result from a variability/defect in thyroid transport across cell membranes as well. In order for T 3 to establish a transcriptional footprint in the brain, both T 3 and T 4 need to move across the blood-brain barrier, in and out of cells. T 4 is taken up by D 2 -containing astrocytes and tanycytes and the resulting locally generated T 3 must then exit these D 2 -containing cells and enter TR-containing neighboring neurons to finally trigger its transcriptional effects [80, 81] . A variability/defect in any of these steps could affect intracellular T 3 content and lead to localized brain hypothyroidism. This is illustrated in patients with the Allan-Herndon-Dudley syndrome, carriers of an inactivating mutation in the X-linked MCT8 gene, a member of the MCT family that preferentially transports T 3 across cell membranes and is highly expressed in several organs including the brain. Patients with this syndrome exhibit psychomotor retardation and neurological impairment, indicating brain-specific hypothyroidism during development [82, 83] .
Other thyroid hormone transporters have been identified, including the blood-brain barrier-specific anion transporter OATP1C1, mainly expressed in capillaries throughout the brain for which T 4 has a high affinity and specificity [8, 11] . In rats, OATP1C1 mRNA and protein are up-or downregulated depending on the T 4 serum levels, suggesting that this transporter plays a role in preserving physiologic concentrations of T 4 (and thus T 3 ) in the brain [84] . Interestingly, a clinical analysis of 141 hypothyroid participants of a randomized clinical trial revealed that OATP1C1 polymorphisms are associated with fatigue and depression but were not linked to neurocognitive dysfunction [85] .
The Third Question: Can a Deficiency in Brain T 3 Be Restored by Treatment with Combined Levothyroxine and Liothyronine Therapy?
There is circumstantial evidence supporting the paradigm that a variability/defect in thyroid hormone transport and/or metabolism could lead to insufficient T 3 in discrete brain areas of levothyroxine-treated patients explaining their residual neurocognitive impairment despite normalization of serum TSH, T 4 and T 3 concentrations. However, what makes this issue particularly challenging is that such a variability/defect(s) would be silenced by a functional thyroid gland, only to become clinically relevant after the onset of hypothyroidism and treatment with levothyroxine. This could be an indication that the small amounts of T 3 contained in thyroid secretion would be sufficient to compensate for such a variability/defect, making it unlikely that levothyroxine alone would restore brain T 3 in such individuals. In fact, even when the transport/metabolism pathways in the rat brain are fully functional, brain T 3 did not increase (and remained fairly stable) in hypothyroid rats receiving a wide range (20-fold) of T 4 doses [36] . In contrast, brain T 3 increased progressively in hypothyroid rats treated with a much narrower range (8-fold) of T 3 doses [86] .
Thus, it is conceivable that administration of liothyronine could restore brain euthyroidism in hypothyroid individuals that remain clinically symptomatic on levothyroxine therapy. For example, if a variability/loss of function mutation in the D 2 pathway or in one of the thyroid hormone transporter genes is behind the persistent psychological impairment, such patients would benefit clinically from taking liothyronine, bypassing the variability/defect. However, even if successful, such a strategy has the obvious caveat that not only the brain but all tissues would be exposed to the additional T 3 , thus essentially creating a state of systemic thyrotoxicosis for life [87] .
A series of clinical trials indicate that a relative elevation in serum T 3 can be achieved by switching patients from monotherapy with levothyroxine to a combined therapy with levothyroxine and liothyronine [87] [88] [89] [90] [91] . The elevation in serum T 3 is variable, depending on the dose of liothyronine used. Multiple combination regimens exist, with levothyroxine:liothyronine ratios being applied at 10: 1 to 5: 1 [87] . A recent meta-analysis of ten such randomized controlled studies confirmed that serum TSH did not vary significantly between the monotherapy and combined therapy groups, but serum FT 4 levels decreased and total serum T 3 increased significantly in the patients switching to combined therapy [92] . In other regimens, relatively less T 3 is used and the switch to combined therapy does not elevate serum T 3 levels [93] . However, given the relatively short T 3 half-life of about 12 h in humans, a normal serum T 3 in the morning actually indicates that during the preceding 24 h the integrated serum T 3 fluctuated at higher levels in the patients receiving combined therapy. In fact, the 24-hour profile of individuals placed on such mild combined therapies indicates that serum free T 3 levels increased significantly, by about 40%, within the first 4-hour post-dose, with an integrated area under the curve for serum free T 3 significantly higher by about 10% [94] . In contrast, there is only a modest 16% rise in serum FT 4 with no change in serum free T 3 in the first 4-hour post-levothyroxine dose [94] .
Despite the logic of this rationale, most randomized clinical trials (with three exceptions [88, 89, 95] ) comparing monotherapy versus combined therapy failed to reveal a statistically significant difference in clinical outcomes [96] . The meta-analysis of eleven studies, in which 1,216 patients were randomized, found no difference in the effectiveness of monotherapy versus combined therapy symptoms such as bodily pain, depression, anxiety, fatigue, quality of life, body weight, total serum cholesterol, triglyceride levels, low-density lipoprotein, and high-density lipoprotein [96] . Yet, even when the objective methods used to assess the well-being of the patients did not uncover a meaningful change, patients did seem to prefer combined therapy [97] .
The discovery of polymorphisms in the genes of the deiodinases and thyroid hormone transporters led to the obvious hypothesis that subgroups of hypothyroid patients respond differently to monotherapy versus combined therapy depending on their genetic makeup. This hypothesis was tested and the results seem encouraging, particularly in the light of a relatively large analysis of 552 individuals in the WATTS study, suggesting that the combined therapy is associated with a favorable clinical outcome in patients exhibiting the Thr92AlaD 2 polymorphism [98] . In the WATTS study, the thyroid hormone formulation used included the simultaneous reduction in the dose of levothyroxine by 50 g/day and the introduction of 10 g/day of liothyronine [98] .
Notably, not all studies involving the Thr92AlaD 2 polymorphism resulted in such clear-cut results [97] . However, given that this D 2 polymorphism is present in a relatively small proportion of the population on levothyroxine, previous studies are likely to have been underpowered to see this effect [97] . Likewise, no differences in appreciation for the combined therapy were observed in a relatively small sample of patients carrying OATP1C1 polymorphisms [85] .
Conclusions
The vast majority of the hypothyroid patients achieve biochemical and clinical euthyroidism on thyroid hormone replacement therapy with levothyroxine alone. A small group of hypothyroid patients on monotherapy with levothyroxine remain clinically symptomatic with impaired neurocognitive functions despite normalization of serum TSH, T 4 and T 3 levels. This could be attributed to localized brain hypothyroidism due to a variability/defect in thyroid hormone transport and/or metabolism. Addition of liothyronine to the treatment regimen could theoretically restore brain euthyroidism and, in fact, depending on the dose of liothyronine used, patients who switched from monotherapy to combined therapy exhibited elevation in serum T 3 . However, a large number of clinical trials did not find improved outcomes with combined therapy. Only recently a polymorphism in the DIO2 gene, which could result in decreased D 2 activity, was taken into consideration. In the WATTS trial, the largest so far, only hypothyroid patients carrying the Thr92AlaD 2 polymorphism exhibited favorable outcomes on combined therapy, indicat-ing that personalized medicine is catching up with thyroid disease. More studies are needed to further evaluate this question, but in the meantime the report of a slowrelease liothyronine preparation seems to offer a more stable T 3 level over time [99, 100] , opening the doors to an appealing new approach to mildly and steadily elevate serum T 3 in some hypothyroid patients to offset variability/defects in thyroid hormone signaling in the brain.
